Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 12 of 12 publications.
Skip to main content
Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res. 2012 Dec;27(12):2429-37. doi: 10.1002/jbmr.1768
Gilsenan AW, Kellier N, Harris DH, Andrews EB, Masica DN. Linking a voluntary patient registry with US state cancer registries for possible signal detection. Poster presented at the 28th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2012. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2012 Aug 27; 21(suppl 3):464. doi: 10.1002/pds.3324
Harris DH, Gilsenan AW, Wu Y, Andrews EB. Using cancer surveillance data to advance science: monitoring for a potential safety signal for approved drugs through linkage studies. Poster presented at the Annual Meeting of the North American Association of Central Cancer Registries; 2012.
Naslund MJ, Gilsenan AW, Midkiff KD, Bown A, Wolford ET, Wang A. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting. Int J Clin Pract. 2007 Sep 1;61(9):1437-45.
Midkiff K, Gilsenan A, Martin R, Masica DN, Andrews E. Characteristics of patients in a postmarketing osteosarcoma surveillance study. Poster presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2007. Quebec City, Canada.
Gilsenan AW, Midkiff K, Wu Y, Martin R, Masica DN, Andrews E. Factors associated with interview completion rates in a surveillance study of osteosarcoma and antecedent exposures. Poster presented at the 23rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 23, 2007. Quebec City, Canada.
Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; August 21, 2007. Quebec City, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2007 Aug 7; 16(Suppl 2):S55. doi: 10.1002/pds.1461
Martin RD, Gilsenan AW, Wu Y, Midkiff KD, Masica DN. Long-term post-marketing studies: flexibility, perseverance and patience. Presented at the North American Association of Central Cancer Registries Annual Meeting; 2007.
Martin RD, Gilsenan AW, Midkiff KD, Wu Y, Andrews EB, Masica DN. Adult osteosarcoma surveillance study: results from a telephone survey with patients identified through central cancer registries. Presented at the North American Association of Central Cancer Registries Annual Meeting; 2007.
Martin RD, Gilsenan AW, Von Scheele BG. International drug safety monitoring using population-based cancer registries. Poster presented at the North American Association of Central Cancer Registries; 2007.
Gilsenan AW, Wang J, Midkiff KD, Andrews EB. Assessing the impact of potential selection bias on prevalence estimates of lower urinary tract symptoms in a primary care setting. Poster presented at the 23rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2007.
Naslund M, Gilsenan AW, Midkiff KD, Wolford E, Bown A, Wang J. The prevalence of luts and prostate enlargement in the primary care setting. Poster presented at the Annual Meeting of the American Urological Association; 2007.